News
Expansion of the peptide hormone antibody portfolio
August 23 2010
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Product launch: new monoclonal antibodies available
May 07 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
Further expansion of our GLP-1 portfolio: Anti-GLP-1 (Non-amidated (-Arg-Gly) C-terminal specific) antibody
June 10 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics is pleased to announce the launch of a new monoclonal antibody ABS 046-03. The new antibody ABS 046-03 recognizes the C-terminus of non-amidated (-Arg-Gly) GLP-1 and shows a low level of cross-reactivity with C-terminally amidated GLP-1.
The active forms of GLP-1 are potent stimulators of glucose-dependent insulin secretion and GLP-1 receptor agonists are strong drug candidates for the treatment of type 2 diabetes. BioPorto Diagnostics’ GLP-1 antibody portfolio provides useful tools for physiological and pharmaceutical research into the therapy of type 2 diabetes, and, as GLP-1 is also involved in the regulation of food intake, in developing treatments for obesity.
The launch of this new antibody brings BioPorto Diagnostics a step closer to being able to offer a complete GLP-1 antibody portfolio, which currently includes unique antibodies for several different GLP-1 forms and related targets such as Exendin-4.
BioPorto Diagnostics is launching this antibody as a part of the AntibodyShop portfolio and expects to expand the GLP-1 group of antibodies even further in the future.
